Pérez-Bermejo, M.; Caballero-Pascual, M.; Legidos-García, M.E.; Martínez-Peris, M.; Casaña-Mohedo, J.; Llorca-Colomer, F.; Ventura, I.; Tomás-Aguirre, F.; Asins-Cubells, A.; Murillo-Llorente, M.T.
Sacituzumab Govitecan in Triple Negative Breast Cancer: A Systematic Review of Clinical Trials. Cancers 2024, 16, 3622.
https://doi.org/10.3390/cancers16213622
AMA Style
Pérez-Bermejo M, Caballero-Pascual M, Legidos-García ME, Martínez-Peris M, Casaña-Mohedo J, Llorca-Colomer F, Ventura I, Tomás-Aguirre F, Asins-Cubells A, Murillo-Llorente MT.
Sacituzumab Govitecan in Triple Negative Breast Cancer: A Systematic Review of Clinical Trials. Cancers. 2024; 16(21):3622.
https://doi.org/10.3390/cancers16213622
Chicago/Turabian Style
Pérez-Bermejo, Marcelino, Mónica Caballero-Pascual, María Ester Legidos-García, Miriam Martínez-Peris, Jorge Casaña-Mohedo, Francisco Llorca-Colomer, Ignacio Ventura, Francisco Tomás-Aguirre, Adalberto Asins-Cubells, and María Teresa Murillo-Llorente.
2024. "Sacituzumab Govitecan in Triple Negative Breast Cancer: A Systematic Review of Clinical Trials" Cancers 16, no. 21: 3622.
https://doi.org/10.3390/cancers16213622
APA Style
Pérez-Bermejo, M., Caballero-Pascual, M., Legidos-García, M. E., Martínez-Peris, M., Casaña-Mohedo, J., Llorca-Colomer, F., Ventura, I., Tomás-Aguirre, F., Asins-Cubells, A., & Murillo-Llorente, M. T.
(2024). Sacituzumab Govitecan in Triple Negative Breast Cancer: A Systematic Review of Clinical Trials. Cancers, 16(21), 3622.
https://doi.org/10.3390/cancers16213622
